Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0F8PG
|
|||
Drug Name |
PMID29334795-Compound-21
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Corticobasal degeneration [ICD-11: 8A00.1Y] | Patented | [1] | |
Progressive supranuclear palsy [ICD-11: 8A00.10; ICD-10: G23.1] | Patented | [1] | ||
Company |
SANOFSANOFI LANGEVIN, Beverly C. FARR, Robert Allan SHAH, Dinubhai H. SHERER, DanieSANOFI-AVENTIS DIAZ MARTIN, Juan Antonio JIMENEZ BARGUENO, Maria Dolores
|
|||
Structure |
Download2D MOL |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Histamine H3 receptor (H3R) | Target Info | . | [1] |
Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Reactome | Histamine receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | Monoamine Transport | |||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.